Erasmus School of Health Policy & Management
Assistant professor | Health Technology Assessment (HTA)
- thielen@eshpm.eur.nl
More information
Work
- Michiel Zietse, Jacky Hu, Esther R. van Staveren, Leontine E.A.M.M. Spierings, Agnes Jager, Birgit C.P. Koch, Ron H.J. Mathijssen, Roelof W.F. van Leeuwen & Frederick W. Thielen (2025) - Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study - Breast, 84 - doi: 10.1016/j.breast.2025.104573 - [link]
- Nicolas Xander, Tom Belleman, Maximilian Salcher-Konrad, Anne Hendrickx, Jeffrey Chen, Anne-Sophie Klein Gebbink, Peter Schneider, Kate Morgan, Oliver Groene, Isabelle Durand-Zaleski, Frederick Thielen & Carin Uyl-de Groot (2025) - Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review - The European Journal of Health Economics - doi: 10.1007/s10198-025-01834-y
- Michiel Zietse, Luuk C Aalders, Leontine E A M M Spierings, Nikki De Rouw, Wouter Dercksen, Virgil A S H Dalm, Esther Oomen-de Hoop, Frederick W Thielen, Birgit C P Koch, Ron H J Mathijssen, Leni van Doorn & Roelof W F van Leeuwen (2025) - Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial - BMJ open, 15 (4), e102770 - doi: 10.1136/bmjopen-2025-102770 - [link]
- M. M.B. Horstink, D. R. Geel, , C. A. den Uil, P. E. Deetman, H. Endeman, A. Abdulla, T. M. Bosch, W. J.R. Rietdijk, F. W. Thielen, J. J. Haringman, P. van Vliet, T. A. Rijpstra, C. Bethlehem, A. Beishuizen, A. E. Muller, B. C.P. Koch, R. Zwinkels, N. Juffermans, N. G.M. Hunfeld, M. Kemper, M. van der Jagt, M. G.J. de Boer, L. Vloet, J. Elderman, I. Nutma, H. Buter, E. Van Haren, C. A. den Uil & C. Boly (2025) - Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial - BMC Infectious Diseases, 25 (1) - doi: 10.1186/s12879-025-10747-3 - [link]
- Michiel Zietse, Thirza Kooijman, Ruben Malmberg, Leontine E A M M Spierings, Agnes Jager, Ron H J Mathijssen, Roelof W F van Leeuwen & Frederick W Thielen (2025) - Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis - JCO Oncology Practice, 21 (9), 1287 - 1295 - doi: 10.1200/OP-24-00804 - [link]
- Sejad Ayyoubi, Liesbeth Ruijgrok, Hugo van der Kuy, Renske Ten Ham & Frederick Thielen (2024) - What Does Pharmaceutical 3D Printing Cost?: A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency - PharmacoEconomics - Open, 9 (2), 207-215 - doi: 10.1007/s41669-024-00551-1 - [link]
- Michiel Zietse, Ruben Malmberg, Roelof W.F. van Leeuwen, Frederick W. Thielen & Carin A. Uyl – de Groot (2024) - The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective - Bmc Health Services Research, 24 (1) - doi: 10.1186/s12913-024-11719-0 - [link]
- R. J.S.D. Heine, F. W. Thielen, R. H.J. Mathijssen, R. W.F. van Leeuwen, M. G. Franken & C. A. Uyl-de Groot (2024) - Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab - PLoS ONE, 19 (2 February) - doi: 10.1371/journal.pone.0293264 - [link]
- Leona Hakkaart - van Roijen, Stijn Peeters, Tim Kanters, Pieter van Baal, Werner Brouwer, Ruben Drost, Silvia M.A.A. Evers, Job van Exel, Vivian Reckers-Droog, Nasr-Eddine Tannaoui, Frederick Thielen & Ben Wijnen (2024) - <b>Kostenhandleiding </b>voor economische evaluaties in de gezondheidszorg:: Methodologie en Referentieprijzen - [link]
- Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
- Lj Bakker, Fw Thielen, WK Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
- Ngoc Do & Frederick W. Thielen (2023) - Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View - Value in Health, 26 (4), 477-486 - doi: 10.1016/j.jval.2022.11.002 - [link]
- Frederick W. Thielen, Renaud J.S.D. Heine, Sibren van den Berg, Renske M.T.ten Ham & Carin A.Uyl de Groot (2022) - Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma - Cytotherapy, 24 (12), 1245-1258 - doi: 10.1016/j.jcyt.2022.09.002 - [link]
- Frederick W. Thielen, Renaud J.S.D. Heine, Sibren Van Den Berg, Renske M.T. Ten Ham & Carin A. Uyl-De Groot (2022) - Kostprijs-plusmodel geeft inzicht in reële prijzen gentherapieën - Pharmaceutisch Weekblad, 157 (47), 18-20 - [link]
- Frederick W. Thielen, Marie José Kersten, Pim Kuizenga, Mels Hoogendoorn, Eduardus F.M. Posthuma, Wendy B.C. Stevens, Carin A Uyl-de Groot & Hedwig M. Blommestein (2021) - Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view - Expert Review of Anticancer Therapy, 21 (12), 1411-1422 - doi: 10.1080/14737140.2021.1971520 - [link]
- Kai Ruggeri, Julia P. Stuhlreyer, Johanna Emilia Immonen, Silvana Mareva, Maja Friedemann, Alessandro F. Paul, Matthew Lee, Rachel C. Shelton, Annalisa Robbiani, Frederick W. Thielen, Amiran Gelashvili, Filippo Cavassini & Faisal Naru (2021) - Policy evaluation and behavioral economics - doi: 10.4324/9781003181873-11 - [link]
- Renaud Heine, Frederick W. Thielen, Marc Koopmanschap, Marie José Kersten, Hermann Einsele, Ulrich Jaeger, Pieter Sonneveld, Jorge Sierra, Carin Smand & Carin A. Uyl-De Groot (2021) - Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future - HemaSphere, 5 (2) - doi: 10.1097/HS9.0000000000000524 - [link]
- Frederick Thielen (2020) - Current Challenges in Health Technology Assessment: Assessing costs and cost-effectiveness of novel treatments in haemato-oncology - [link]
- Frederick Thielen (2018) - Best Student Poster Presentation
- WF (Frederick) Thielen (2013) - ESST European Award for Aspiring Undergraduates
Advanced Health Economic Modelling
- Year Level
- master, master, master
- Year
- 2025
- Course Code
- GW4563M
Advanced Health Economic Modelling EuHEM
- Level
- master
- Year Level
- master
- Year
- 2025
- Course Code
- GW4587M
Pharmaceutical Pricing and Market Access
- Year Level
- master, master, master, master
- Year
- 2025
- Course Code
- GW4575M
ESHPM HEPL-HE
- Year
- 2025
- Course Code
- GWMTTHEPL
